vTv Therapeutics
VTVTvTv Therapeutics is a late-stage biopharmaceutical company dedicated to developing orally administered small-molecule therapies for metabolic and inflammatory diseases.
Table of contents
Earnings
Next report
Aug 11, 2026 (in a month)Competitors
By market cap
By revenue growth
By net margin
Profile
vTv Therapeutics is a late-stage biopharmaceutical company dedicated to developing orally administered small-molecule therapies for metabolic and inflammatory diseases. The company's primary focus is advancing its lead candidate, a liver-selective glucokinase activator, as an adjunctive treatment to insulin for patients with type 1 diabetes. By targeting glycemic control and reducing hypoglycemic events, the company aims to improve clinical outcomes for patients with chronic metabolic conditions.
A late-stage clinical developer with FDA Breakthrough Therapy designation for its lead metabolic candidate.
Questions, answered.
- What is vTv Therapeutics's market cap?
- vTv Therapeutics (VTVT) has a market capitalization of $131.7M and trades on NASDAQ.
- Who are vTv Therapeutics's competitors?
- vTv Therapeutics's key competitors include Eli Lilly and Company, Novo Nordisk, Sanofi, and others. These companies compete in similar markets and product categories.
- Who does vTv Therapeutics partner with?
- vTv Therapeutics's notable partners include G42 Investments AI Holding RSC Ltd..
- Where is vTv Therapeutics headquartered?
- vTv Therapeutics is headquartered in United States of America and employs approximately 16 people. It has been publicly traded since 2015.